http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2699261-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f1ef6f1a6319f01bb92d09c61a4f0e76 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-401 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-401 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 |
| filingDate | 2014-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3484d2ba59658e9cab3e8be400135e6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c671fbd86db43de61629212bf1ef7bd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_329959587f4e088a6f02139a14bd7310 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d075e042832d971eb1dc7515bd684a9c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2287daac0c76cf7bd3a605c3f86e427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96ddc8ae41d36cde891c6da6944cb037 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d4124889fe4516e1e94b1e345e883a7 |
| publicationDate | 2019-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2699261-T3 |
| titleOfInvention | Derivatives of sulfamoylpyrrollamide and its use as medicines for the treatment of hepatitis b |
| abstract | A compound of Formula (ID) ** Formula ** or a stereoisomer or a tautomeric form thereof, where: each X independently represents CR7; Ra, Rb and Rc are independently selected from the group consisting of Hydrogen, Fluoro, Bromo, Chloro, - CHF2, -CF2-methyl, -CH2F, -CF3, -OCF3, -CN, C1-C3 alkyl and C3-C4 cycloalkyl; Rd is Hydrogen or Fluoro; R4 is Hydrogen, C1-C3 alkyl or C3-C4 cycloalkyl; R5 is Hydrogen; R6 is selected from the group consisting of C2-C6 alkyl, (C1-C4 alkyl) -R8 optionally substituted with one or more Fluoro moieties, (C1-C4 alkyl) -R9 optionally substituted with one or more Fluoro moieties, and a saturated ring 3-7 membered mono- or polycyclic optionally containing one or more heteroatoms independently each selected from the group consisting of O, S and N, said 3-7 membered saturated ring or said C2-C6 alkyl optionally substituted with one or more substituents independently selected each from the group consisting of Hydrogen, -OH, Fluoro, oxo, R9, R10 and C1-C4 alkyl optionally substituted with R10; R7 represents Hydrogen, -CN, Fluoro, Chlorine, Bromo, -CHF2, -CF2-methyl, -CH2F, -CF3, C1-C3 alkyl optionally substituted with methoxy, C2-C3 alkenyl or C3-C4 cycloalkyl; R8 represents a 3-7-saturated saturated ring that optionally contains one or more heteroatoms independently each selected from the group consisting of O, S and N, said 3-7-saturated saturated ring being optionally substituted with one or more alkyl moieties C1-C4 optionally substituted with R10; R9 represents C1-C4 alkyloxy, -SO2-methyl, -C (= O) -OR11 or -C (= O) -N (R11) 2; R10 represents -CN, -OH, Fluoro, -CHF2, -CH2F or -CF3; R11 represents hydrogen or C1-C3 alkyl; or a pharmaceutically acceptable salt or solvate thereof, wherein said compound is not ** Formula ** |
| priorityDate | 2013-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 90.